
News|Articles|February 6, 2026
Staging, Surgery, and Emerging Targeted Strategies in Chondrosarcoma: Your Key Clinical Questions Answered
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Kirsty Mackay
Philippos Costa, MD, and Hari Deshpande, MD, discuss chondrosarcoma staging, diagnosis, surgery, and future research avenues in this clinician-focused FAQ.
Advertisement
Advertisement
On International Chondrosarcoma Awareness Day, OncLive sat down with Philippos Costa, MD; and Hari Deshpande, MD, to discuss frequently asked questions (FAQ) about the complexities of chondrosarcoma management. The following FAQ, adapted from their conversation, provide clinical insights into chondrosarcoma staging, diagnosis, and disease biology; the importance of surgery as the primary treatment for localized chondrosarcoma; and the potential role for IDH1-targeted therapy and DR5 agonists in this rare disease subtype.
Related to this article

Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement

